4 completed, 3 recruiting, 1 active not recruiting, 1 enrolling by invitation. 6 Not applicable, 3 Phase 2, 2 Phase 3, 1 Phase 4.
Follow Opioid Use Disorder, Severe: new trials by email Literature Review of Opioid Use Disorder, Severe trials Research Report on Opioid Use Disorder, Severe
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Family-Focused Study to Support Medication for Opioid Use Disorder FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate | Not applicable | Not yet recruiting | University of Wisconsin, Madison | 338 | 2027-08-31 | 2026-07-07 |
| TRTME: Improving Outpatient Initiation of Medication for Opioid Use Disorder Following Hospitalization TRTME - Opioid Use Disorder, Opioid Use Disorder, Moderate | Not applicable | Enrolling by invitation | T. John Winhusen, PhD | 30 | 2026-08-19 | 2026-09-28 |
| Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses Standard of Care Referral, Low Threshold Buprenorphine - Opioid Use Disorder, Opioid Use Disorder, Severe | Not applicable | Recruiting | Montefiore Medical Center | 512 | 2026-08-17 | 2026-10-01 |
| Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder Tirzepatide, Placebo - Opioid Use Disorder, Opioid Use Disorder, Moderate | Phase 2 | Recruiting | T. John Winhusen, PhD | 310 | 2026-01-29 | 2026-08-11 |
| Applying Low-Intensity Focused Ultrasound in Treating Severe Substance Use Disorder: Tolerability and Effectiveness Low-intensity focused ultrasound, false stimulus - Opioid Use Disorder, Severe, Amphetamine Use Disorder | Not applicable | Recruiting | National Taiwan University Hospital | 60 | 2025-01-01 | 2026-07-31 |
| EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy Low Intensity, High Intensity - Substance Use Disorders, Opioid Use Disorder, Severe | Not applicable | Active not recruiting | Gavin Bart | 24 | 2021-10-22 | 2026-04-23 |
| EXHIT ENTRE Comparative Effectiveness Trial Extended Release Buprenorphine, Treatment as Usual - Substance Use Disorder, Opioid Use Disorder, Moderate | Phase 2 / Phase 3 | Completed | Gavin Bart | 344 | 2021-08-09 | 2025-12-09 |
| A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals BNI Chatbot, OUD Education & Treatment Resources - Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe | Not applicable | Completed | Center for Progressive Recovery, LLC | 4 | 2021-08-01 | 2024-07-03 |
| Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder CBOT + TAU, Sham + TAU - Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe | Phase 2 | Unknown | Evon Medics LLC | 190 | 2021-03-26 | 2021-08-06 |
| Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders Non invasive VN stimulation (nVNS), Oxygen (15-O) Water, Sham Stimulation - Substance-Related Disorders, Substance Use Disorders | Phase 3 | Completed | Emory University | 20 | 2020-11-13 | 2023-09-13 |
| SUBLOCADE Rapid Initiation Extension Study Sublocade - Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate | Phase 4 | Completed | Indivior Inc. | 17 | 2019-10-21 | 2025-03-25 |
Opioid-Related Disorders (11) · Lymphoma, Follicular (9) · Substance-Related Disorders (3) · Criminal Behavior (1) · Substance Abuse, Intravenous (1) · Substance Withdrawal Syndrome (1)
Chemically-Induced Disorders (11) · Mental Disorders (11) · Narcotic-Related Disorders (11) · Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoma (9) · Lymphoma, Non-Hodgkin (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Substance-Related Disorders (8) · Behavior (1)
Standard of Care (2) · Dosage Forms (1) · Educational Status (1) · Oxygen (1) · Oxygen-15 (1) · Sublocade (1) · Therapeutics (1) · Tirzepatide (1) · Ultrasonic Waves (1) · Water (1) · salicylhydroxamic acid (1)
Gavin Bart (2) · T. John Winhusen, PhD (2) · Center for Progressive Recovery, LLC (1) · Emory University (1) · Evon Medics LLC (1) · Indivior Inc. (1) · Montefiore Medical Center (1) · National Taiwan University Hospital (1) · University of Wisconsin, Madison (1)
United States (10) · Taiwan (1)
Gavin Bart, MD,PhD (2) · T. John Winhusen, PhD. (2) · Aaron D Fox, MD, MS (1) · Edwin Chapman, MD (1) · Evaristus A Nwulia, MD (1) · J Douglas Bremner, MD (1) · Marc Fishman, MD (1) · Mark Johnson, MD (1) · Michael Hassman (1) · Michael Serlin, MD (1) · Michael V Pantalon, PhD (1) · Tanya Alim, MD (1) · Todd Molfenter, PhD (1)
PMID 36041704, PMID 37936553, PMID 38600571, PMID 39623502, PMID 40548916
2025 (1), 2UG1DA040316-06 (1), 3UG1DA013035-24S1 (1), 5UG1DA040316-05 (1), R43DA051267 (1), R44DA049616 (1), R61DA061326 (1), UG1DA013732 (1), UG3DA048502 (1)